Inhibition of p70S6K1 will improve the life of T2D patients, as it is a downstream effector of mTOR, which mediates glucose homeostasis, protein synthesis, RNA processing, cell growth and apoptosis [156]. This evidence concerns the gene RPS6KB1 and type 2 diabetes mellitus.